PRR14: A Potential Drug Target and Biomarker (G78994)

Target Name: PRR14

NCBI ID: G78994

PRR14

PRR14: A Potential Drug Target and Biomarker

Proline-rich proteins (PRPs) are a class of biomarkers that have been identified as potential drug targets in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. PRRs are a type of protein that contain a high proportion of proline residues, which are structurally diverse and can play a variety of roles in cellular signaling pathways.

One of the main advantages of PRPs as drug targets is their ability to interact with a wide range of signaling pathways, including those involved in cell division, angiogenesis, and inflammation. This makes them attractive targets for small molecules, which can modulate their activity without affecting the cell as a whole. Additionally, PRPs are often overexpressed in diseases, which can make them more accessible as drug targets.

PRR14, also known as proline-rich gene 14, is a gene that encodes a protein that is rich in proline residues. The protein encoded by PRR14 has been shown to play a role in several cellular processes, including cell signaling, DNA replication, and repair.

One of the key features of PRR14 is its ability to interact with the protein p21, which is a tumor suppressor protein that plays a role in the regulation of cell growth and apoptosis. p21 is often overexpressed in cancer, and studies have suggested that PRR14 may be a potential drug target for cancer treatment.

In addition to its potential as a cancer drug target, PRR14 has also been shown to be involved in several other cellular processes that are important for human health. For example, PRR14 has been shown to play a role in the regulation of cell division and differentiation, which are important for the development and maintenance of tissues and organs.

PRR14 has also been shown to be involved in the regulation of cell signaling pathways, including those involved in cell growth, angiogenesis, and inflammation. This makes it a potential target for small molecules that can modulate its activity and potentially have therapeutic effects on a wide range of diseases.

In conclusion, PRR14 is a gene that has been shown to encode a protein that is rich in proline residues and has been implicated in several cellular processes that are important for human health. Its potential as a drug target makes it an attractive target for small molecules that can modulate its activity and potentially have therapeutic effects on a wide range of diseases. Further research is needed to fully understand the role of PRR14 in cellular processes and its potential as a drug target.

Protein Name: Proline Rich 14

Functions: Functions in tethering peripheral heterochromatin to the nuclear lamina during interphase, possibly through the interaction with heterochromatin protein CBX5/HP1 alpha (PubMed:24209742). Might play a role in reattaching heterochromatin to the nuclear lamina at mitotic exit (PubMed:24209742). Promotes myoblast differentiation during skeletal myogenesis, possibly by stimulating transcription factor MyoD activity via binding to CBX5/HP1 alpha (PubMed:25906157). Involved in the positive regulation of the PI3K-Akt-mTOR signaling pathway and in promoting cell proliferation, possibly via binding to GRB2 (PubMed:27041574)

The "PRR14 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PRR14 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets